The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients

Plain-language summary

This study looks at the role of DNA and RNA in next-generation sequencing (NGS) analyses using bronchial lavage samples in patients with advanced-stage non-small cell lung cancer (NSCLC). Adults aged 18 and older with suspected stage IV lung cancer on CT/PET imaging who need NGS testing may take part. The study does not use a clinical phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Intervention

bronchial lavage for NGS analysis

Start date

1/17/2025

Estimated completion

10/31/2025

Countries

Italy

Related genes

Locations

• Bologna, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥ 18 years;
* Indication for bronchoscopic cytological sampling for further diagnosis of suspected stage IV lung cancer on CT (computed tomography)/PET (positron emission tomography) scans, with consequent need for NGS analysis.
* Indication for bronchoscopy in patients with known lung cancer who have already undergone NGS analysis on a cytological-histological sample in the previous five years.
* Acquisition of written informed consent.

Exclusion Criteria:

* Confirmation of small cell lung cancer or other non-NSCLC pathology where there is no indication for NGS testing.